On the cusp of change: New therapeutic modalities for HCV
Journal Title: Annals of Hepatology - Year 2010, Vol 9, Issue 0
Abstract
We are at the cusp of significant new alternatives for the treatment of chronic hepatitis C. Among more than 100 drugs in development, some are ready to be approved and in the market as soon as next year. The protease inhibitors Telaprevir and Boceprevir, will change the SOC treatment to triple therapy, (combined with peg IFN and RBV), with duration of treatment guided by rapid virological response. In this article we present the data supporting the approval of Telaprevir and Boceprevir, and information on polymerase inhibitors and IFN free proof of concept trials. Finally we discuss which patients should wait for DAA based therapies and which should be considered for peg IFN/RBV now. In the next 5 years our patients can expect higher response rates and truncated duration of therapy. They can expect drug cocktails or combos but for the next years these novel drugs will still require peg IFN and RBV. Also, a new era of resistance as a barrier to therapy will require sub typing and more viral monitoring. Overall, improved outcomes will come at the expense of more adverse events and increased costs of treatment.
Authors and Affiliations
Maribel RodrÃguez-Torres
Keywords
Related Articles
- EP ID EP77976
- DOI -
- Views 109
- Downloads 0
Updating the knowledge of hepatitis E: new variants and higher prevalence of anti-HEV in Argentina
Introduction. Hepatitis E is a disease of global distribution, with significant morbidity and mortality, whose scope and burden continue to emerge in low endemic countries. Material and methods. In 2012, we studied the p...
Hepatotoxicity associated with statins
Rhombencephalitis by Listeria monocytogenes in a cirrhotic patient: a case report and literature review
We report a case of rhombencephalitis infection by Listeria monocytogenes in a 66-year-old man with cirrhosis. The CSF analysis indicated L. monocytogenes as the most likely pathogen. Blood and CSF culture were positive...
Efficacy and safety of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy
Background and aims. Patients with intrahepatic cholestasis of pregnancy (ICP) benefit from ursodeoxycholic acid (UDCA) treatment. Since there is still certain reluctance to use UDCA in pregnant women, mainly due to war...
High clinical manifestation rate in an imported outbreak of hepatitis E genotype 1 infection in a German group of travellers returning from India
Background. There are only few reports about travel-associated, imported tropical hepatitis E virus (HEV) genotype 1 infectionswithin Western travellers. We describe the clinical course of a single outbreak of hepatitis...